Erratum: The coming era of quadrivalent human influenza vaccines: Who will benefit? (Drugs (2012) DOI: 10.2165/11641110-000000000-00000);The coming era of quadrivalent human influenza vaccines: Who will benefit?

Drugs

Volumn 72, Issue 17, 2012, Pages 2177-2185

  Barr, Ian G ^a   Jelley, Lauren L ^a  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

Author keywords

Influenza virus infections; Influenza virus vaccines; Paediatric infections; Vaccines.; Errata; Vaccines

Indexed keywords

ASTRAZENECA; INFLUENZA VACCINE; MIFAMURTIDE; PLACEBO; UNCLASSIFIED DRUG;

ASTHMA; AVIAN INFLUENZA; BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DRUG SAFETY; HEART MUSCLE INJURY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; META ANALYSIS; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STAPHYLOCOCCUS AUREUS; VACCINATION; WHEEZING;

EID: 84870044640     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11641110-000000000-00000     Document Type: Erratum

References (60)

1. US Food and Drug Administration. Center for Biologics Evaluation and Research. Vaccines and Related Biological Products Advisory Committee. Meeting Transcript February 28, 2007. Strain selection for the influenza virus vaccine for the 2007-2008 season [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/07/transcripts/2007-4282t2.htm. [Accessed 2012 Jun 6]
2. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010 Aug 6; 59 (RR-8): 1-62 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm?s-cid= rr5908a1-w/[Accessed 2012 Oct 18]
3. Osterholm MT, Kelley NS, Sommer AF, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-Analysis. Lancet Infect Dis 2012; 12 (1): 36-44
4. Britain becomes first country to offer free flu vaccine to all UK kids. Huffpost Healthy Living 2012 Jul 25 [online]. Available from URL: http://www.huffingtonpost.com/2012/07/25/britain-flu-vaccine-kids-united- kingdom-n-170 1363.html [Accessed 2012 Jul 26]
5. Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344: 889-96
6. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28: 3929-35
7. Belshe RB, Coelingh K, Ambrose CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 29: 2149-56
8. Shaw MW, Xu X, Li Y, et al. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 2002; 3003: 1-8
9. Barr IG, Komadina N, Durrant C, et al. Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. CDI 2006; 30 (3): 350-7
10. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012 Jan; 8 (1): 81-8
11. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2012; 28s: D45-53
12. Rota PA, Hemphill ML, Whistler T, et al. Antigenic and genetic characterization of the haemagglutinins of recent cocirculatign straisn of influenza B virus. J Gen Virol 1992 Oct; 73 (Pt 10): 2737-42
13. Chen JM, Guo YJ, Wu KY, et al. Exploration of the emergence of the Victoria Lineage of influenza B virus. Arch Virol 2007; 152: 415-22
14. WHO Collaborating Centre for Reference and Research on Influenza [online]. Available from URL: http://www.in fluenzacentre.org [Accessed 2012 Oct 18]
15. Osterhaus AD, Rimmelzwaan GF, Martina BE, et al. Influenza B virus in seals. Science 2000; 288 (5468): 1051-3
16. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003; 36: 299-305
17. Esposito S, Cantarutti L, Molteni CG, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect 2011; 62 (5): 379-87
18. Hite LK, Glezen WP, Demmler GJ, et al. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza b virus. Int J Infect Dis 2007; 11: 40-7
19. Principi N, Esposito S, Gasparini R, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004; 89: 1002-7
20. Shen CF, Huang SC, Wang SM, et al. Decreased leukocytes and other characteristics of laboratory findings of influenza virus infections in children. J Microbiol Immunol Infect 2008; 41: 294-300
21. Daley AJ, Nallusamy R, Isaacs D. Comparison of influenza A and influenza B virus infection in hospitalized children. J Paediatr Child Health 2000; 36: 332-5
22. Thompson WW, Shay DK, Weintraub E, et al. Mortality assocciated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86
23. Centres for Disease Control and Prevention (CDC). Influenza-Associated pediatric deaths: United States, September 2010-August 2011. MMWR Morb Mortal Wkly Rep 2011 Sep 16; 60 (36): 1233-8
24. Finelli L, Fiore A, Dhara R, et al. Influenza-Associated pediatric mortality in the United States: increase of Staphylococcus aureus co-infection. Pediatrics 2008; 122: 805-11
25. Streng A, Grote V, Liese JG. Severe influenza cases in paediatric intensive care units in Germany during the prepandemic seasons 2005 to 2008.BMCInfect Dis 2011; 11: 233
26. Huang QS, Lopez L, Adlam B. Influenza surveillance in New Zealand in 2005. N Z Med J 2007 Jun 15; 120 (1256): U2581
27. Forty-two people killed by B-type flu: CDC. Focus Taiwan News Channel 7 Feb 2012 [online]. Available from URL: http://focustaiwan.tw/ShowNews/WebNews- Detail.aspx? Type=aALL&ID=201202070052 [Accessed 2012 Feb 8]
28. Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis 2012; 205 (6): 895-904
29. Bowdes R, de Mutsert G, van der Klis FR, et al. Prevalance of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol 2011; 18: 469-76
30. Couch RB. Background and presentation of possible vaccine options. Presented at: Food and Drug Administration, Center for Biologics Evaluation and Research, Vaccine and Related Biological Products Advisory Committee Meeting; 2007 Feb 27-28; Washington, DC
31. Beran J,Wertzova V, Honegr K, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example.BMCInfect Dis 2009; 9: 2
32. Frey S, Vesikari T, Szymczakiewc-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51: 997-1004
33. US Department of Health and Human Services. US Food and Drug Administration. FDA approves first quadrivalent vaccine to prevent seasonal influenza [media release]. 2012 Feb 29 [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm [Accessed 2012 Mar 30]
34. GlaxoSmithKline. Regulatory update: GSK announces submissions for two influenza vaccines [media release]. 2012 Mar 5 [online]. Available from URL: http://us.gsk. com/html/media-news/pressreleases/2012/2012-pressrelease-963603. htm [Accessed 2012 Oct 18]
35. 2011 Document de Reference Sanofi [online]. Available from URL: http://www.sanofi.com/Images/29805-Doc-Ref-2011.pdf [Accessed 2012 Oct 18]
36. Annual results 2011. Sanofi, 2012 Feb 8 [online]. Available from URL: http://en.sanofi.com/Images/29602-2012-02-08-Results-2011-presentation.pdf [Accessed 2012 Oct 18]
37. International Federation of Pharmaceutical Manufacturers and Associations [online]. Available from URL: http://www.ifpma.org [Accessed 2012 Oct 18]
38. MedImmune LLC. A study to evaluate the immunogenicity of quadrivalent LAIV in adults 18 to 49 years of age (MICP185). [ClinicalTrials.gov identifier NCT00860067]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
39. MedImmune LLC. A study to evaluate the immunogenicity of quadrivalent LAIV (MEDI8662) in adults 18 to 49 years of age (MI-CP206) [ClinicalTrials.gov identifier NCT00952705]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
40. MedImmune LLC. A study to evaluate the immunogenicity of quadrivalent live attenuated iInfluenza vaccine (LAIV) in children [ClinicalTrials.gov identifier NCT01091246]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
41. GlaxoSmithKline. A study to evaluate the safety and immunogenicity of GSK Biological's seasonal influenza vaccine in children [ClinicalTrials.gov identifier NCT01198756]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
42. GlaxoSmithKline. A study to evaluate the efficacy of GSK Biological's influenza vaccine in children [Clinical-Trials.gov identifier NCT01218308]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
43. GlaxoSmithKline. A study to evaluate the safety and immunogenicity of GSK Biological's seasonal influenza vaccine in adults [ClinicalTrials.gov identifier NCT01196975]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
44. Sanofi-Aventis. Study of quadrivalent influenza vaccine among children [ClinicalTrials.gov identifier NCT01240746]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
45. Sanofi-Aventis. A study of influenza vaccines in children and adults [ClinicalTrials.gov identifier NCT00988143]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
46. Sanofi-Aventis. Study of quadrivalent influenza vaccine among adults [ClinicalTrials.gov identifier NCT01218646]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 6]
47. Della Cioppa G, Vesikari T, Sokal E, et al. Trivalent and quadrivalent MF59-Adjuvanted influenza vaccine in young children: a dose and schedule finding study. Vaccine 2011; 29: 8696-704
48. Block SL, Yi T, Sheldon E, et al. A randomized, double blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011; 29: 9391-7
49. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31 (7): 745-51
50. Sanofi Pasteur presents pediatric data on investigational quadrivalent influenza vaccine: pediatric data supplements prior phase II and phase III studies in adults [media release]. 2012 May 1 [online]. Available from URL: http://sanofipasteurus.mediaroom.com/index.php?s=11069&item =127633 [Accessed 2012 Jun 1]
51. Reed C, Meltzer M, Finelli L, et al. Public health impact of including two influenza B strains in seasonal vaccines. Options for the Control of Influenza VII; 2010 Sep 3-7; Hong Kong SAR, China, P-570: 388-9
52. Partridge J, Kieny MP. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 2010; 28 (30): 4709-12
53. Reed C, Meltzer MI, Finelli L, et al. Pulic health impact of including to lineages of influenza B in a quadrivalent seasonal influenza vaccines. Vaccine 2012; 30: 1993-8
54. Schnirring L. Early flu-vaccine production forecast: up to 149 million doses. CIDRAP 2012 May 31 [online]. Available from URL: http://www.cidrap.umn. edu/cidrap/con tent/influenza/general/news/may3112fluvax-br.html [Accessed 2012 Jun 22]
55. Landry N, Ward BJ, Trépanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010 Dec 22; 5 (12): e15559
56. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok-) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011 Oct 13; 29 (44): 7733-9
57. Treanor JJ, Taylor DN, Tussey L, et al. Safety and immunogenicity of a recombinant hemagglutinin influenzaflagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010 Dec 6; 28 (52): 8268-74
58. WHO. Recommended composition of influenza virus vaccines for use in the 2013 southern hemisphere influenza season [online]. Available from URL: http://www.who.int/influenza/vaccines/virus/recommendations/2013-south/en/index. html [Accessed 2012 Sep 21]
59. Meeting of the Strategic Advisory Group of Experts on immunization, April 2012: conclusions and recommendations. WHO Weekly Epidemiological Record 2012 May 25; 87 (21) 201-16 [online]. Available from URL: http://www.who.int/wer/ 2012/wer8721.pdf [Accessed 2012 Oct 18]
60. Kilbourne ED, Shulman JL, Schild GC, et al. Related studies of a recombinant influenza-virus vaccine: I. Derivation and characterization of virus and vaccine. J Infect Dis 1971; 124 (5): 449-62